跳至主要内容
临床试验/NCT02622100
NCT02622100终止不适用

Evaluation of Effectiveness and Safety of Bioresorbable Vascular Scaffold in Routine Clinical Practice; A Multicenter, Prospective Observational Study

Duk-Woo Park, MD14 个研究点 分布在 1 个国家目标入组 629 人开始时间: 2016年2月26日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
发起方
入组人数
629
试验地点
14
主要终点
Composite event

研究概览

简要总结

The purpose of this study is to evaluate the relative effectiveness and safety of Bioresorbable Vascular Scaffold compared to other (drug eluting stents) DES.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 19 and more
  • Intervention with Bioresorbable Vascular Scaffold
  • Agreed with written informed consent form

排除标准

  • Bypass graft surgery (CABG) recommended
  • Lesion with previous bypass graft surgery (CABG)
  • Severe calcification and/or severe tortuosity
  • Contraindication to antiplatelet agent or Inability to take dual antiplatelet therapy within 1 year
  • Life expectancy of 1year and under
  • Subjects scheduled to receive cardiac surgery or serious non-cardiac surgery
  • Cardiac shock

结局指标

主要结局

Composite event

时间窗: 1 year

The number of events with the first occurrence of a composite event(death, non-fatal myocardial infarction, target vessel revascularization)

次要结局

  • cardiac death(5 years)
  • Composite event of death or myocardial infarction(5 years)
  • Stroke(5 years)
  • all death(5 years)
  • myocardial infarction(5 years)
  • Target Vessel revascularization(5 years)
  • Composite event of cardiac death or myocardial infarction(5 years)
  • Target Lesion revascularization(5 years)
  • Stent thrombosis(5 years)
  • Procedural success(3 days)

研究者

发起方
Duk-Woo Park, MD
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Duk-Woo Park, MD

Principal investigator

Asan Medical Center

研究点 (14)

Loading locations...

相似试验

Evaluation of Effectiveness and Safety of... | 临床试验